Xencor Reaches Research Milestone (BW Healthwire)–June 17, 2002—Monrovia, CA – Xencor today announced that it has reached a major milestone in its research agreement with Syngenta’s (NYSE: SYT) Torrey Mesa Research Institute (TMRI). In just six months, half the time agreed upon, Xencor has created

- Strategic collaboration announced for bispecific programs: Novartis to receive ex-U.S. rights to XmAb®14045 and XmAb®13676, Xencor to retain U.S. commercial rights -- XmAb®18087 and XmAb®20717 named as two XmAb® bispecific oncology candidates for treatment of neuroendocrine tumors and multiple cancers, respectively; on track to have four bispecific programs in clinic in 2017 -

-- Commenced multi-dose part of Phase 1a trial of XmAb®7195 examining IgE reduction and safety profile - -- Study with subcutaneous formulation of XmAb7195 to begin in 2016 - -- XmAb®13676 named as second XmAb® bispecific clinical candidate for development in B-cell malignancies - MONROVIA, Calif.

Multiple T-cell engaging bispecific programs show potential as disease modifying treatments for acute myelogenous leukemia, B-cell lymphomas and leukemia, and multiple myeloma Xencor designates its first bispecific antibody candidate, XmAb14045 an anti-CD123xCD3, for IND-enabling studies MONROVIA,

Xencor Prices Initial Public Offering MONROVIA, Calif. , Dec. 3, 2013 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR ) today announced the pricing of its initial public offering of 12,730,000 shares of its common stock at a public offering price of $5.50 per share.

-- Vudalimab was generally well-tolerated; objective responses observed across multiple tumor types -- -- Confirmed partial responses observed in two of four evaluable castration-resistant prostate cancer patients with measurable disease -- -- Additional complete response observed in patient with

MONROVIA, Calif. --(BUSINESS WIRE)--Dec. 6, 2020-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, today announced updated data from its ongoing Phase 1 dose-escalation study of

-- XmAb20717 was generally well-tolerated; 19% objective response rate (ORR) observed across cohorts at the recommended dose level -- -- Early clinical activity, including prostate-specific antigen (PSA) reductions in patients with advanced prostate cancer, support initiation of new Phase 1b study

Rapid IgE clearance by XmAb7195 shows potential as a disease modifying treatment for allergy and asthma

Drug well tolerated with early signs of efficacy in heavily pretreated Hodgkin lymphoma patient population